Analyzing kidney injury risk in septic shock patients
Does the Urine Concentration of TIMP2*IGFBP7 Can Distinguish Patients Who Will Present Transient or Persistent Acute Kidney Injury During Septic Shock? A Retrospective Analysis. BIOCHECK
This study looks at patients in intensive care with septic shock to see if certain urine markers can help predict the risk of kidney injury and how likely it is to get better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 170 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Trial ID | NCT03472079 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with septic shock in intensive care units who are at high risk for developing acute kidney injury (AKI). The researchers will analyze data from patients admitted between January 2014 and January 2017, specifically looking at urine concentrations of TIMP2*IGFBP7 to assess the likelihood of AKI reversibility. By determining a threshold for these biomarkers, the study aims to differentiate between transient and severe kidney injuries, potentially guiding early interventions. The study is retrospective and will utilize existing patient data to draw conclusions about kidney function recovery.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over who have been diagnosed with septic shock and acute kidney injury within a specific timeframe.
Not a fit: Patients requiring immediate renal replacement therapy or those with chronic renal failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early interventions for patients with septic shock, potentially reducing mortality associated with acute kidney injury.
How similar studies have performed: While the approach of using TIMP2*IGFBP7 for early AKI detection is promising, it is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or over * Inclusion criteria: septic shock (according to Bone's criteria) within 4 hours following the introduction of catecholamines, AKI defined by KDIGO≥1, social security coverage, measurement of the urine concentration of TIMP2\*IGFBP7 within the 4 hours following the introduction of catecholamines, patients admitted for a septic shock between 1st January 2014 and 1st January 2017 in the medical ICU of Amiens university hospital France, medical ICU of Montpellier university hospital France and ICU Melun hospital, France Exclusion Criteria: * Need for immediate renal replacement therapy, anuria, chronic renal failure (stage 4 or 5 with GFR\<30ml/min), obstructive AKI, pregnancy, cardiac arrest during the same hospitalization, life expectancy\<48 hours, Child C Cirrhosis, prior occurrence of AKI during the current hospital stay, kidney transplantation.
Where this trial is running
Amiens
- CHU Amiens-Picardie — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Julien Maizel, Pr
- Email: maizel.julien@chu-amiens.fr
- Phone: +33 3 22 08 78 07
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.